Skip to content
Adagene logo — Redefining the design and discovery
of therapeutic antibodie...

Adagene

Redefining the design and discovery of therapeutic antibodies

Founded 2012 81 employees IPO Total: $390.00M Biotechnology, Health and Wellness

General Information

Company Name Adagene
Founded Year 2012
Employees 81
Industries Biotechnology, Health and Wellness
Funding Stage IPO
Business Model B2B, Platform, B2B2B
Revenue Model Licensing, Service Fee, Performance Based
Offices as of Nov 2026
CN Jiangsu Suzhou Industrial Park, 215123
Social

BounceWatch is an independent company data service, not affiliated with Adagene. To contact Adagene, visit adagene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Adagene compare?

A PDF of Adagene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Adagene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Oct 28, 2026

Adagene collaborates with Incyte in a Phase 1 study evaluating muzastotug and INCA33890 for colorectal cancer.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a pioneering biotechnology company established in 2012, with a commitment to transforming the design and discovery of antibody-based cancer immunotherapies. The company’s slogan, "Redefining the design and discovery of therapeutic antibodies," underscores its innovative approach in this specialized field.

Central to Adagene's advancements is its proprietary DPL platform, which includes NEObody, SAFEbody™, and POWERbody™ technologies. These elements facilitate the creation of novel antibodies, tailored to address critical unmet patient needs. The company's strategic collaborations with prominent global partners highlight its ability to leverage cutting-edge technologies in novel immunotherapy programs.

Adagene recently secured a $70.00M Post IPO Equity investment on 01 April 2026 from notable investors including Invus, Columbia Threadneedle Investments, Janus Henderson Investors, Deerfield, and Sirenia Aps, indicating strong confidence in its potential to revolutionize cancer treatment.

Business keywords: antibody discovery, cancer immunotherapy, computational biology, DPL platform, NEObody technology, SAFEbody technology, POWERbody technology, immuno-oncology, novel epitopes, Smart Antibody Technology, clinical-stage biotech, therapeutic antibody development, strategic collaborations

Services & Products

Antibody Discovery
Antibody Engineering
Drug Development

Target Customers

Pharmaceutical Companies Healthcare Institutions Biotech Investors

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $70.00M 5
Invus, Columbia Threadneedle Investments +3
01 Apr 2026
Post-IPO Equity $25.00M 1
Sanofi
01 Jul 2025
IPO $140.00M -
01 Feb 2021
Series D $69.00M 3
Eight Roads Ventures, General Atlantic +1
01 Jan 2020
Series C $50.00M 5
Gopher Asset Management, World Fund +3
01 Mar 2018
Series B $28.00M 3
F-Prime Capital, WuXi Healthcare Ventures +1
01 Jan 2016
Series A $8.00M 2
F-Prime Capital, WuXi Healthcare Ventures
01 Dec 2014
Early VC Undisclosed 1
Eight Roads Ventures
01 Jan 2011

Adagene Alternatives & Competitors

View All Alternatives
Adagene vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology
Adagene vs

Hummingbird Bioscience is a biotherapeutics company working at the interface of AI and human innovat...

Series C
90 employees
Biotechnology, Health Care
Adagene vs
Relay Therapeutics
Relay Therapeutics United States

Integrating leading-edge computational and experimental science to transform human health.

IPO
230 employees
Biotechnology, Health Care

FAQ About Adagene

Redefining the design and discovery of therapeutic antibodies
Adagene was founded in 2012.
Adagene operates in Biotechnology and Health and Wellness. Its work centres on antibody discovery, cancer immunotherapy, computational biology and DPL platform. Its customers include Pharmaceutical Companies, Healthcare Institutions and Biotech Investors.
Adagene has a B2B, Platform and B2B2B business model. Its revenue comes from Licensing, Service Fee and Performance Based.
Adagene has approximately 81 employees.
Adagene has completed 8 funding rounds, raising a total of $390.00M. The latest funding stage is IPO.
Adagene offers: Antibody Discovery, Antibody Engineering, Drug Development.
Top alternatives and competitors to Adagene include OncoResponse, Hummingbird Bioscience, Relay Therapeutics, Xilio Therapeutics, Inc., NBE-Therapeutics AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adagene and OncoResponse are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adagene, https://www.bouncewatch.com/company/adagene, updated 7 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout